Tim R Cressey1, Anchalee Avihingsanon2, Guttiga Halue3, Prattana Leenasirimakul4, Pra-Ornsuda Sukrakanchana5, Yardpiroon Tawon5, Nirattiya Jaisieng5, Gonzague Jourdain1, Anthony T Podany6, Courtney V Fletcher6, Virat Klinbuayaem7, Chureeratana Bowonwatanuwong8. 1. Program for HIV Prevention and Treatment, Faculty of Associated Medical Sciences, Chiang Mai University, Thailand Harvard School of Public Health, Boston, Massachusetts Institut de Recherche pour le Développement UMI 174-Program for HIV Prevention and Treatment, Marseille, France. 2. HIV Netherlands Australia Thailand Research Collaboration, Thai Red Cross AIDS Research Centre Division of Allergy and Immunology, Faculty of Medicine, Chulalongkorn University, Bangkok. 3. Phayao Hospital. 4. Nakornping Hospital, Chiang Mai, Thailand. 5. Program for HIV Prevention and Treatment, Faculty of Associated Medical Sciences, Chiang Mai University, Thailand. 6. Antiviral Pharmacology Laboratory, College of Pharmacy, University of Nebraska Medical Center, Omaha. 7. Sanpatong Hospital, Chiang Mai. 8. Chonburi Hospital, Thailand.
Abstract
BACKGROUND: The approved tenofovir disoproxil fumarate (TDF) dose of 300 mg every 48 hours for adults with moderate renal impairment is often confusing and inconvenient. Using a new TDF formulation, we compared the pharmacokinetics of the standard dose with a dose of 150 mg once daily in HIV-infected adults. METHODS: This was an open-label pharmacokinetic study. Virologically suppressed HIV-infected adults with a creatinine clearance 30 to <50 mL/minute receiving TDF 300 mg every 48 hours as part of a nonnucleoside reverse transcriptase inhibitor (NNRTI)- or lopinavir/ritonavir (LPV/r)-based regimen were enrolled. Intensive 48-hour blood sampling for pharmacokinetic assessment was performed at enrollment, after which the TDF dose was changed to 150 mg once daily. Two weeks later, 24-hour blood sampling was performed; subjects then returned to the standard dose. Tenofovir (TFV) pharmacokinetic parameters were calculated using a noncompartmental analysis. RESULTS: Forty adults (55% female) were enrolled: 20 receiving NNRTI-based and 20 receiving LPV/r-based treatment. Median age was 56 years (range, 44-65 years), weight 51 kg (range, 38-80 kg), and creatinine clearance 43.9 mL/minute (range, 30.9-49.7 mL/minute). The TFV geometric mean ratio of the area under the curve (AUC0-48 h) for every 24 hours vs every 48 hours was 1.09 (90% confidence interval [CI], .98-1.22) and 1.00 (90% CI, .92-1.09) for patients receiving NNRTI- and LPV/r-based treatment, respectively. Concomitant LPV/r use markedly increased TFV plasma concentrations, and AUC0-48 h was 67% higher with the standard dose, whereas no differences in intracellular TFV diphosphate concentrations were observed. All subjects remained virologically suppressed, and no drug-related adverse events were reported. CONCLUSIONS: TDF 150 mg every 24 hours provides comparable systemic exposure to the standard dose of 300 mg every 48 hours in patients with moderate renal impairment. CLINICAL TRIALS REGISTRATION: NCT01671982.
BACKGROUND: The approved tenofovir disoproxil fumarate (TDF) dose of 300 mg every 48 hours for adults with moderate renal impairment is often confusing and inconvenient. Using a new TDF formulation, we compared the pharmacokinetics of the standard dose with a dose of 150 mg once daily in HIV-infected adults. METHODS: This was an open-label pharmacokinetic study. Virologically suppressed HIV-infected adults with a creatinine clearance 30 to <50 mL/minute receiving TDF 300 mg every 48 hours as part of a nonnucleoside reverse transcriptase inhibitor (NNRTI)- or lopinavir/ritonavir (LPV/r)-based regimen were enrolled. Intensive 48-hour blood sampling for pharmacokinetic assessment was performed at enrollment, after which the TDF dose was changed to 150 mg once daily. Two weeks later, 24-hour blood sampling was performed; subjects then returned to the standard dose. Tenofovir (TFV) pharmacokinetic parameters were calculated using a noncompartmental analysis. RESULTS: Forty adults (55% female) were enrolled: 20 receiving NNRTI-based and 20 receiving LPV/r-based treatment. Median age was 56 years (range, 44-65 years), weight 51 kg (range, 38-80 kg), and creatinine clearance 43.9 mL/minute (range, 30.9-49.7 mL/minute). The TFV geometric mean ratio of the area under the curve (AUC0-48 h) for every 24 hours vs every 48 hours was 1.09 (90% confidence interval [CI], .98-1.22) and 1.00 (90% CI, .92-1.09) for patients receiving NNRTI- and LPV/r-based treatment, respectively. Concomitant LPV/r use markedly increased TFV plasma concentrations, and AUC0-48 h was 67% higher with the standard dose, whereas no differences in intracellular TFV diphosphate concentrations were observed. All subjects remained virologically suppressed, and no drug-related adverse events were reported. CONCLUSIONS:TDF 150 mg every 24 hours provides comparable systemic exposure to the standard dose of 300 mg every 48 hours in patients with moderate renal impairment. CLINICAL TRIALS REGISTRATION: NCT01671982.
Authors: Diane T Holland; Robin DiFrancesco; Judith Stone; Fayez Hamzeh; James D Connor; Gene D Morse Journal: Antimicrob Agents Chemother Date: 2004-03 Impact factor: 5.191
Authors: Trevor Hawkins; Wenoah Veikley; Robert L St Claire; Bill Guyer; Nicole Clark; Brian P Kearney Journal: J Acquir Immune Defic Syndr Date: 2005-08-01 Impact factor: 3.731
Authors: Sudeep P Pushpakom; Neill J Liptrott; Sonia Rodríguez-Nóvoa; Pablo Labarga; Vincent Soriano; Marta Albalater; Elizabeth Hopper-Borge; Stefano Bonora; Giovanni Di Perri; David J Back; Saye Khoo; Munir Pirmohamed; Andrew Owen Journal: J Infect Dis Date: 2011-07-01 Impact factor: 5.226
Authors: J A H Droste; C P W G M Verweij-van Wissen; B P Kearney; R Buffels; P J Vanhorssen; Y A Hekster; D M Burger Journal: Antimicrob Agents Chemother Date: 2005-02 Impact factor: 5.191
Authors: Adrian S Ray; Tomas Cihlar; Kelly L Robinson; Leah Tong; Jennifer E Vela; Michael D Fuller; Lani M Wieman; Eugene J Eisenberg; Gerry R Rhodes Journal: Antimicrob Agents Chemother Date: 2006-10 Impact factor: 5.191
Authors: Tim R Cressey; Oraphan Siriprakaisil; Rachel W Kubiak; Virat Klinbuayaem; Pra-Ornsuda Sukrakanchana; Justice Quame-Amaglo; Hideaki Okochi; Yardpiroon Tawon; Ratchada Cressey; Jared M Baeten; Monica Gandhi; Paul K Drain Journal: Int J Infect Dis Date: 2020-06-14 Impact factor: 3.623
Authors: Xinhui Chen; Sharon M Seifert; Jose R Castillo-Mancilla; Lane R Bushman; Jia-Hua Zheng; Jennifer J Kiser; Samantha MaWhinney; Peter L Anderson Journal: PLoS One Date: 2016-11-10 Impact factor: 3.240